Tag: medical marijuana

States That Legalized Medical Marijuana Saw Nearly 20 Percent Drop In Foster Care Cases For Parental Drug Misuse, Study Finds

States that legalized medical marijuana saw a nearly 20 percent drop in the number of children entering foster care due to parental drug misuse after three years of the reform, a new study found. Legalizing for adult use, meanwhile, was not associated with any statistically significant change in foster care entries.

Researchers at Georgia College and State University set out to learn whether legalization would “lessen stigma, permit proper use, and reduce the chance that a child will be removed” or, conversely, if foster care cases would increase due to expanded access to legal cannabis.

The study looked at national data involving 3.4 million foster care cases from 2007 to 2019. Using difference-in-differences analyses, researchers examined rate changes in foster case placements related to drug misuse, comparing states that enacted legalization to those that maintained prohibition. They controlled for factors such as state unemployment rate and per capita income.

“Our estimates suggest that when states permitted recreational marijuana use, there was no corresponding change in the number of foster care entries related to parental or teenage drug abuse relative to control states,” the study says.

But for states that legalize medical cannabis, there was a discernible shift. In the first two years of implementation, states saw an average eight percent to 10 percent decrease in foster care cases connected to drug misuse. By the third year, cases dropped 18 percent, which amounted to “approximately 700 fewer entries to foster care [that] were related to parental drug abuse when a state legalized medical marijuana.”

That’s an especially important finding given that 90 percent of foster case entries due to drug misuse happen in states where medical cannabis is legal, says the study, which is pending peer review. Drug misuse is the second most common reason that a child is placed into foster care.

The study also compared states that have restrictive versus comprehensive medical cannabis programs, but researchers said they are “hesitant to draw conclusions” about the differences because of conflicting data using two analytic models.

For limited medical marijuana states, there was a “sizable decrease” in foster care drug misuse cases in the third and fourth year after implementation based on one difference-in-difference model, but that effect was less pronounced in the other model.

States with less restrictive medical cannabis legalization laws, in contrast, showed a “statistically and economically significant decrease in the number of entries” in one model, but data from the other model was less clear.

“Our findings suggest that states which legalized medical marijuana experienced a decrease in parental drug abuse-related entries into foster care in the initial years following the legalization compared to states that did not legalize medical marijuana,” the study says. “Estimates exploiting variation in state-level limitations on medical marijuana are mixed.”

Keep reading

Young People At Risk Of Psychosis Saw Symptoms ‘Surprisingly’ Improve With Marijuana Use, Study Finds

A new study of teens and young adults at risk of developing psychotic disorders found that regular marijuana use over a two-year period did not trigger early onset of symptoms—contrary to the claims of prohibitionists who argue that cannabis causes mental illness. In fact, it was associated with modest improvements in cognitive functioning and reduced use of other medications.

A team of researchers at Zucker Hillside Hospital, Stanford University School of Medicine, University of Michigan and University of California at Davis carried out the study, which was published Tuesday in the journal Psychiatry Research.

“Recreational cannabis use has recently gained considerable interest as an environmental risk factor that triggers the onset of psychosis,” the study authors wrote. “To date, however, the evidence that cannabis is associated with negative outcomes in individuals at clinical high risk (CHR) for psychosis is inconsistent.”

To investigate, the team tracked 210 CHR patients ages 12–25 who participated in an Early Detection and Intervention for the Prevention of Psychosis Program (EDIPPP). Over the course of two years, researchers compared the mental health and prescription medication usage of people who regularly consumed marijuana to non-users.

The study found that “continuous cannabis use over 2-years of follow-up was not associated with an increased psychosis transition rate, and did not worsen clinical symptoms, functioning levels, or overall neurocognition.”

“Nevertheless, our findings suggest that continuously using cannabis may be associated with slightly elevated, albeit non-significant, attenuated positive symptom levels relative to non-users,” the researchers said.

“CHR youth who continuously used cannabis had higher neurocognition and social functioning over time, and decreased medication usage, relative to non-users,” they reiterated. “Surprisingly, clinical symptoms improved over time despite the medication decreases.”

Keep reading

Medical Marijuana Company Slams DEA In Lawsuit Alleging Extreme Delays To Cannabis Research Licensing

A company focused on developing marijuana-derived pharmaceuticals is suing the Drug Enforcement Administration (DEA) over what it calls “exponential delays” in the agency’s process for granting licenses to grow cannabis for medical research.

Rhode Island-based MMJ BioPharma Cultivation Inc. filed a petition for a writ of mandamus in the U.S. Court of Appeals for the D.C. Circuit on Friday, alleging that DEA’s yearslong licensing application process has hamstrung the company’s business and stymied innovation that could benefit patients. It’s asking the federal court to compel the agency to act.

“Despite beginning this process in November of 2017,” the company says in the lawsuit, “MMJ has been unable to conduct the research that it was created to do.”

MMJ is working to produce a gel capsule containing cannabis extracts, which it says is intended to treat multiple sclerosis and Huntington’s disease. While it previously received DEA authorization to import marijuana into the U.S. from Canada, MMJ later applied for permission to cultivate cannabis in-house for research and development purposes.

“This registration is essential to MMJ’s ability to conduct FDA-sanctioned clinical trials,” the company says, “because without the ability to cultivate their own marijuana, they are unable to produce the proper compound.”

MMJ asserts that DEA’s pre-registration investigation for the license application began in June 2021 and lasted through the following October. “At the end of the visit, the diversion investigator informed MMJ that they would return to the DEA office, ‘write up’ the report, and submit the report to their group supervisor who would then submit those findings to DEA Headquarters for a final determination,” the suit says.

But according to the petition, no final determination ever came. “Despite numerous attempts to follow-up and check the status of the registration approval determinations for manufacturing, DEA personnel have expressed to MMJ that they have not yet made final determinations and they have no idea when that determination will be made,” it says.

Keep reading

Medical Marijuana Use Linked To Improved Quality Of Life And Better Job Performance For People With Neurological Disorders, New Study Finds

Medical marijuana use is associated with improved quality of life—including better job performance, sleep, appetite and energy—according to a new study.

Researchers at the University of West Attica in Greece published the study in the journal GeNeDis Neuroscientific Advances on Wednesday following an analysis of survey data from medical cannabis patients with neurological disorders.

“Medical cannabis has been used to relieve the symptoms of people with various chronic diseases,” the authors said. “Despite this, it has been stigmatized.”

The study showed that a majority (58 percent) of respondents said medical cannabis is an effective treatment for their condition.

Among that group, 96 percent said that marijuana decreased their symptoms, 88 percent said it improved their “ability to perform their professional duties,” 79 percent said it enhanced their sleep, 71 percent said it improved their appetite and 68 percent said it increased their energy and vitality.

“Our participants exhibited very few restrictions in activities due to emotional difficulties, a moderate general health status as well as moderate vitality and energy,” the study authors said. “Participants, who reported a longer period of receiving medical cannabis, reported statistically significant more energy and vitality, but also better mental and general health status.”

The clinical questionnaire and SF-36 Health Survey scale that respondents completed also asked about their openness about using cannabis for therapeutic purposes.

A strong majority (85 percent) of medical marijuana patients said that they’ve disclosed their use to family—and 93 percent said that they “enjoyed their support.” However, 81 percent said that they haven’t been open about their cannabis use in their “social environment” such as their workplace.

“Appropriate knowledge could significantly help health professionals in the field of planning and implementation of personalized nursing care in order to achieve optimal therapeutic outcomes,” the study concludes.

The findings are consistent with other recent research indicating that cannabis can play a role in improving general wellbeing.

Keep reading

States With Legal Medical Marijuana See ‘Significant And Sizable’ Reductions In Health Insurance Premiums, Study Finds

A new study in the International Journal of Drug Policy found that states with legal medical marijuana enjoyed significant reductions in health insurance premiums compared to states where cannabis remained completely illegal.

Analyzing a decade’s worth of private health insurance data from the National Association of Insurance Commissioners, researchers determined that in the years following a state’s implementation of a medical cannabis law, premiums dropped dramatically.

While the reductions were modest immediately following implementation, the study found that by seven years afterward, annual premiums had fallen $1,663 compared to states in the control group. Similar reductions were seen after eight years ($1,542) and nine years ($1,626), indicating that the decline was fairly stable over time.

“Although the effect does not begin until seven years post-medical cannabis law implementation,” the authors conclude, “there is a significant and sizable reduction in health insurance premiums” in states that legalize medical marijuana.

“Due to the nature of insurance pooling and community rating,” they add, “these savings are appreciated by cannabis users and non-users alike.”

As the study’s authors point out, the findings undermine concerns that legalization would risk increasing healthcare costs. “Initial concerns about medical cannabis legalization leading to increases in medical care costs, which would be reflected in higher insurance premiums, appear to be unfounded,” they wrote.

Researchers were specifically looking at individual private health plans rather than employer-sponsored insurance plans or Medicaid. The study notes that health insurance spending in the U.S. accounts for between 16 percent and 34 percent of the average household budget.

In an attempt to control for other variables, authors focused on states where only medical marijuana was legal, excluding from the analysis states where adult-use legalization was already in effect. States in the control group, meanwhile, included those without medical cannabis or those that had passed but not yet implemented a such a policy

Keep reading

Arkansas Law Protecting Medical Marijuana Patients’ Gun Rights Officially Takes Effect

A new law officially takes effect in Arkansas on Tuesday to clarify that medical marijuana patients can obtain concealed carry licenses for firearms.

The governor signed the bill in April, just days after it sailed through the legislature with strong majority support.

The newly effective law stipulates that a person’s status as a qualified medical cannabis patient in the state cannot be used “in determining whether an applicant is eligible to be issued a license to carry a concealed handgun.”

State statute has also been amended to clarify that participation in the medical marijuana program doesn’t mean that a person is a chronic or habitual user of a controlled substance, which could otherwise disqualify people from obtaining the concealed carry permit.

The state Department of Health (DOH) will be barred from disclosing a person’s patient status to the state police as part of any investigation into concealed carry eligibility.

While some states have moved to more broadly preserve firearm rights for cannabis patients and consumers, the new law signed by Gov. Sarah Huckabee Sanders (R) is more narrowly tailored to the concealed carry issue.

Arkansas does not require people to have a permit for concealed carry, but some Arkansas firearms owners prefer to have one because of the protections it can bestow when traveling in other states and because of the clarity it provides during police encounters.

Keep reading

VA And Defense Department Oppose Medical Marijuana For PTSD, But Take Neutral Position On Psychedelics As Research Continues

The U.S. Department of Veterans Affairs (VA) and Department of Defense (DOD) are strongly against the use of marijuana for the treatment of post-traumatic stress disorder (PTSD)—but they’re taking a neutral position on psychedelics like psilocybin and LSD, simply saying that more research should be done.

In an update to their joint clinical practice guidelines, the departments provided recommendations on a variety of therapeutics used to treat PTSD and acute stress disorder that commonly afflict military veterans. And while many veterans use marijuana, often to treat symptoms of the conditions, the VA/DOD Management of Posttraumatic Stress Disorder and Acute Stress Disorder Work Group said it is fully against the alternative treatment option.

“The Work Group recommends against the use of cannabis or cannabis derivatives in treating patients with PTSD because of the lack of well-designed [randomized control trials] evaluating the efficacy of cannabis derivatives in large samples of individuals with PTSD and the serious side effects associated with their use,” it says.

“Evidence from the 2017 VA/DoD PTSD [clinical practice guidelines] indicates significant harm associated with cannabis use,” it said, arguing that research suggests that marijuana is linked to issues with attention, memory, IQ and driving.

While medical marijuana came with a “strong against” recommendation from the departments, they said that the work group’s confidence in the existing evidence is “very low” due to a “lack of randomized, controlled, methodologically sound clinical trials; small sample sizes, and selection bias.”

“The benefits of cannabis were outweighed by the potential serious adverse effects,” the document, published last month, says. “Patient values and preferences varied largely because some patients seek new, novel treatments although others might be unwilling to use cannabis or cannabis derivatives. Thus, the Work Group made the following recommendation: We recommend against cannabis or cannabis derivatives for the treatment of PTSD.”

Keep reading

States With Legal Weed See Drop in Mental Health Treatment

States that have legalized recreational marijuana use for adults have also seen a drop in mental health treatment admissions, according to newly published research.

The findings, which came in a study published last month in the journal Health Economics, were based on data from ten states that have legalized adult-use cannabis. 

“Recreational marijuana laws (RMLs) continue to grow in popularity, but the effects on mental health treatment are unclear,” wrote Alberto Ortega, a professor at O’Neill School of Public Health at Indiana University and the author of the study.

In the abstract, Ortega said that the study “uses an event-study within a difference-in-differences framework to study the short-run impact of state RMLs on admissions into mental health treatment facilities.” 

“The results indicate that shortly after a state adopts an RML, they experience a decrease in the average number of mental health treatment admissions,” Ortega wrote. “The findings are driven by white, Black, and Medicaid-funded admissions and are consistent for both male and female admissions. The results are robust to alternative specifications and sensitivity analysis.”

Keep reading

Medical Marijuana Improves Military Veterans’ Quality Of Life And Reduces Prescription Drug Use, Study Finds

Over 90 percent of U.S. military veterans who use medical marijuana say that it improves their quality of life, with many using cannabis as an alternative to over-the-counter and prescription medications, according to a new study.

Researchers at the University of Massachusetts, University of Utah and cannabis research institutes looked at self-reported survey data from 510 veterans who said that they consume marijuana, seeking to better understand the purpose and experiences of their usage.

A majority of the respondents (67 percent) said that they use cannabis daily. And about one-third (30 percent) said that they consume marijuana to reduce the use of other medications, including anti-depressants (25 percent) and non-steroidal anti-inflammatories (17 percent). Another 21 percent said that cannabis has allowed them to reduce their use of opioid-based medications.

Overall, 91 percent of the veterans said that cannabis improved their quality of life.

“Veterans who were Black, who were female, who served in active combat, and who were living with chronic pain were more likely to report a desire to reduce the number of prescription medications they were taking,” the study says. “Women and individuals who used cannabis daily were more likely to report active use of cannabis to reduce prescription medication use.”

“Medicinal cannabis use was reported to improve quality of life and reduce unwanted medication use by many of the study participants. The present findings indicate that medicinal cannabis can potentially play a harm-reduction role, helping veterans to use fewer pharmaceutical medications and other substances.”

The observational study, which was published last month in the journal Clinical Therapeutics, has several limitations—including the fact that data was self-reported and several cannabis friendly media outlets and companies promoted recruitment or provided funding for the research initiative. But the findings are generally consistent with other studies that have focused on marijuana as a potential alternative to prescription drugs.

There’s particular interest in studying the possibility of cannabis as a treatment option for veterans, as the population disproportionately suffers from post-traumatic stress disorder (PTSD) and high rates of suicide.

Keep reading

GOP Congresswoman Pushes For Psychedelics And Marijuana Research For Veterans In Floor Speech

A GOP congresswoman is touting recently released Food and Drug Administration (FDA) guidance on psychedelics research and calling for additional work to study the therapeutic benefits of marijuana for military veterans.

In a speech on the House floor on Wednesday, Rep. Mariannette Miller-Meeks (R-IA) talked about the need to support “novel forms of research” to unlock the potential of psychedelics and cannabis for the treatment of conditions like post-traumatic stress disorder (PTSD) that commonly afflict veterans.

“As a doctor, former director of the Iowa Department of Public Health and 24-year U.S. Army veteran, the mental, emotional and physical health of my constituents and fellow veterans is one of my top priorities in Congress,” she said. “For too long, PTSD and other mental or physical ailments have had devastating effects and far too often go untreated.”

Keep reading